Extended Data Fig. 2: Analysis of neuroendocrine and non-neuroendocrine NPPO organoid lines.
From: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
a, VIPER-inferred activity of indicated proteins in the composite NPPO organoid dataset. b, Pathway analysis using VIPER inferred activities; 10 selected pathways are also shown in Fig. 1g. c, Western blot of RB1 and phospho-RB1 expression in NPPO organoid lines. d, Epigenomic changes in NPPO-1nonNE, NPPO-7, NPPO-8, and NPPO-9 organoid lines after enzalutamide treatment; these nonNE lines display an AR-low CRPC phenotype. Organoid lines were cultured in the absence of DHT. The levels of NSD2, NSD3, as well as H3K36me2 and H3K27me3 were detected by immunofluorescence staining. AR, Androgen receptor; CHGA, Chromogranin A; SYP, Synaptophysin; VIM, Vimentin. Scale bars, 50 µm.
